These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 72239

  • 1. An experiment to determine the active therapeutic moiety of sulphasalazine.
    Azad Khan AK, Piris J, Truelove SC.
    Lancet; 1977 Oct 29; 2(8044):892-5. PubMed ID: 72239
    [Abstract] [Full Text] [Related]

  • 2. The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis.
    Willoughby CP, Piris J, Truelove SC.
    Scand J Gastroenterol; 1980 Oct 29; 15(6):715-9. PubMed ID: 7010522
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
    Klotz U, Maier K, Fischer C, Heinkel K.
    N Engl J Med; 1980 Dec 25; 303(26):1499-502. PubMed ID: 6107853
    [Abstract] [Full Text] [Related]

  • 4. Sulphasalazine retention enemas in ulcerative colitis: a double-blind trial.
    Palmer KR, Goepel JR, Holdsworth CD.
    Br Med J (Clin Res Ed); 1981 May 16; 282(6276):1571-3. PubMed ID: 6113021
    [Abstract] [Full Text] [Related]

  • 5. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
    Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA.
    Gut; 1988 May 16; 29(5):669-74. PubMed ID: 2899536
    [Abstract] [Full Text] [Related]

  • 6. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial.
    Friedman LS, Richter JM, Kirkham SE, DeMonaco HJ, May RJ.
    Am J Gastroenterol; 1986 Jun 16; 81(6):412-8. PubMed ID: 3518408
    [Abstract] [Full Text] [Related]

  • 7. Evolution of olsalazine.
    Truelove SC.
    Scand J Gastroenterol Suppl; 1988 Jun 16; 148():3-6. PubMed ID: 2906475
    [Abstract] [Full Text] [Related]

  • 8. 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis.
    Andreoli A, Spinella S, Levenstein S, Prantera C.
    Ital J Gastroenterol; 1994 Apr 16; 26(3):121-5. PubMed ID: 7914759
    [Abstract] [Full Text] [Related]

  • 9. Refractory distal ulcerative colitis responsive to 5-aminosalicylate enemas.
    Barber GB, Lee DE, Antonioli DA, Peppercorn MA.
    Am J Gastroenterol; 1985 Aug 16; 80(8):612-4. PubMed ID: 2862789
    [Abstract] [Full Text] [Related]

  • 10. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis.
    Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tampieri M, Iannone P, Miglioli M, Barbara L.
    Gut; 1991 Aug 16; 32(8):929-31. PubMed ID: 1885075
    [Abstract] [Full Text] [Related]

  • 11. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.
    van Hees PA, Bakker JH, van Tongeren JH.
    Gut; 1980 Jul 16; 21(7):632-5. PubMed ID: 6107263
    [Abstract] [Full Text] [Related]

  • 12. Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis.
    d'Albasio G, Trallori G, Ghetti A, Milla M, Nucci A, Pacini F, Morettini A.
    Dis Colon Rectum; 1990 May 16; 33(5):394-7. PubMed ID: 1970284
    [Abstract] [Full Text] [Related]

  • 13. Topical treatment of distal ulcerative colitis with 4-amino-salicylic acid enemas.
    Selby WS, Bennett MK, Jewell DP.
    Digestion; 1984 May 16; 29(4):231-4. PubMed ID: 6381186
    [Abstract] [Full Text] [Related]

  • 14. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
    Rachmilewitz D.
    BMJ; 1989 Jan 14; 298(6666):82-6. PubMed ID: 2563951
    [Abstract] [Full Text] [Related]

  • 15. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?
    Bird HA.
    Br J Rheumatol; 1995 Nov 14; 34 Suppl 2():16-9. PubMed ID: 8535642
    [Abstract] [Full Text] [Related]

  • 16. Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls.
    Lauritsen K, Hansen J, Bytzer P, Bukhave K, Rask-Madsen J.
    Gut; 1984 Nov 14; 25(11):1271-8. PubMed ID: 6149981
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of leucocyte motility by drugs used in ulcerative colitis.
    Rhodes JM, Bartholomew TC, Jewell DP.
    Gut; 1981 Aug 14; 22(8):642-7. PubMed ID: 6116649
    [Abstract] [Full Text] [Related]

  • 18. Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas. A double-blind, placebo-controlled trial.
    Ginsberg AL, Beck LS, McIntosh TM, Nochomovitz LE.
    Ann Intern Med; 1988 Feb 14; 108(2):195-9. PubMed ID: 3277506
    [Abstract] [Full Text] [Related]

  • 19. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.
    Green JR, Mansfield JC, Gibson JA, Kerr GD, Thornton PC.
    Aliment Pharmacol Ther; 2002 Jan 14; 16(1):61-8. PubMed ID: 11856079
    [Abstract] [Full Text] [Related]

  • 20. Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis.
    Willoughby CP, Cowan RE, Gould SR, Machell RJ, Stewart JB.
    Scand J Gastroenterol Suppl; 1988 Jan 14; 148():40-4. PubMed ID: 2906476
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.